On This Day in Health: June 14, 2024
On June 14, 2024, the U.S. Food and Drug Administration approved durvalumab, sold by AstraZeneca as Imfinzi, with chemotherapy for adults with certain advanced or recurrent endometrial cancers in the United States. The authorized sequence combined the immunotherapy with carboplatin and paclitaxel, followed by durvalumab alone. It applied specifically to cancers with deficient mismatch repair, commonly abbreviated dMMR. The decision added an option for a defined group of patients whose disease had either presented at an advanced stage or returned. It also highlighted the growing role of tumor testing in deciding which cancer treatments have the strongest supporting evidence for a particular patient population.
Endometrial cancer begins in the lining of the uterus. When disease is advanced or recurs, treatment decisions depend on more than its original location. Mismatch repair is one of the cellular systems that correct errors in DNA, and a deficiency can give tumors biological characteristics relevant to immune treatment. Durvalumab is an antibody that blocks PD-L1, part of a pathway that can restrain immune responses against cancer. The June approval therefore joined an immune checkpoint treatment to established chemotherapy rather than replacing chemotherapy at the outset. Identifying the tumor's repair status was essential to understanding the authorization; the result could not simply be generalized to every person with endometrial cancer.
The evidence came from DUO-E, a randomized, double-blind study with several treatment groups. Patients received chemotherapy with durvalumab or placebo, followed by maintenance treatment, while another group tested an additional investigational combination. Tumor mismatch-repair status was assessed with an immunohistochemistry tissue test. Although the overall study population showed improved progression-free survival with the durvalumab regimen, the FDA attributed the overall improvement primarily to the dMMR subgroup in an exploratory analysis. Among 95 patients with dMMR tumors, the median progression-free interval had not yet been reached in the durvalumab group at the analysis, compared with seven months in the placebo group. Not reached meant that the median could not yet be estimated from the available follow-up, rather than that progression had become impossible.
Overall-survival findings were still immature when progression-free survival was analyzed. Treatment also carried adverse effects, including neuropathy, nausea, fatigue and other problems associated with the combined regimen. Those qualifications were important parts of the evidence, alongside the improvement in disease control. The June milestone did not represent a universal cure or the first use of immunotherapy in this cancer. It marked a further move toward selecting therapy using biological features of a tumor. Its longer significance lies in the connection between pathology and treatment: a laboratory assessment could help define the population for an authorized regimen, while clinical follow-up remained necessary to understand benefit, tolerability and outcomes over time.
Mismatch repair corrects certain DNA errors. A deficient repair system can help identify a tumor subgroup with different treatment responses.
The June authorization covered primary advanced or recurrent endometrial cancer with dMMR, rather than every endometrial tumor.
The approved sequence used durvalumab with carboplatin and paclitaxel, then durvalumab as maintenance without those chemotherapy agents.
A median progression-free survival that is not reached reflects incomplete observation of that midpoint; it does not establish permanent protection.
The decision linked an immunohistochemistry tumor assessment with a specific treatment pathway, illustrating the clinical role of biomarkers.
Overall-survival results were immature at the supporting analysis, and tolerability remained important alongside evidence of delayed progression.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.